Related to Lpath Puts the Brakes on Two Ophthalmology Trials due to Manufacturing Issues

• Cell Therapeutics Signs Manufacturing Deal for Pixantrone with NerPharMa
  
• Elusys Extends Manufacturing Agreement with Lonza for Its Anthrax Treatment
  
• LBL to Supply Proliant BSA to Small-Scale Customers
  
• Daiichi Sankyo Becomes First Firm to License BioWa and Lonza’s Fucose-Free mAb Cell Line
  
• CMC Biologics to Manufacture ProtAffin’s Preclinical-Stage IL-8 Decoy
  
• Taligen Pockets $10M to Move Candidate for Autoimmune Diseases into the Clinic
  
• Lonza Acquires Vivante to Expand into Viral-Based GMP Manufacturing
  
• Lonza Provides GSK with Manufacturing Capacity for Five Clinical-Stage mAbs
  
• CIRM to Dole Out $72M to Advance Research and Recruit Stem Cell Scientist
  
• Sinovac Wins $1.8M Chinese Flu Vaccine Contract and Gets Anflu Sanctioned in Hong Kong
  
• Tate & Lyle to Manufacture Farnesene for Amyris
  
• Dalton and Lonza Ink Contract Chemistry and Manufacturing Agreement
  
• Bayer and Regeneron Say VEGF Trap-Eye Improves Treatment of Wet AMD
  
• Stason to Use Lonza’s Gene-Expression System with TNT Antibody Platform
  
• PanOptica Raises $30M in Series A and Licenses Neovascular AMD Candidate
  
• Dalton to Provide Aseptic Fill/Finish Services to AdeTherapeutics
  
• Boehringer Ingelheim to Purchase Amgen’s Fremont Manufacturing Site
  
• Alexion Pads Biologic R&D with $111M Acquisition of Taligen
  
• Nitto Denko Acquires Avecia for Nucleic Acid Drug Manufacturing Capabilities
  
• Elan and BI Ink Deal for Development and Manufacture of Antibody Therapeutics